All In Biotech

Drug Trial Radar · NCT03761108

Phase 1/2 Study of Linvoseltamab in Adult Patients With Relapsed or Refractory Multiple Myeloma

Phase 1/2 FIH Study of REGN5458 (Anti-BCMA x Anti-CD3 Bispecific Antibody) in Patients With Relapsed or Refractory Multiple Myeloma

Last checked: Nov 20, 2026Latest source record: Oct 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

387

Planned (sponsor's estimate)

Start

Jan 23, 2019

Primary completion

Mar 30, 2033

Study completion Jun 16, 2033

Sponsor

Lead sponsor
Regeneron PharmaceuticalsRegeneron (REGN)
Sponsor type
Industry
First posted
Dec 3, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The main purpose of this study is to learn about the safety of linvoseltamab and to find out what is the best dose of linvoseltamab to give to patients with multiple myeloma and to look for any signs that linvoseltamab can effectively treat cancer. The study is looking at several other research questions, including: * Side effects that may be experienced by people receiving linvoseltamab * How linvoseltamab works in the body * How much linvoseltamab is present in the blood * How linvoseltamab may work to treat cancer

Conditions

  • Multiple Myeloma

Interventions

  • LinvoseltamabDrug

    Administered per the protocol

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of dose-limiting toxicities (DLTs) from the first dose through the end of the DLT observation periodTime frame: Up to 28 days
  2. Incidence and severity of treatment-emergent adverse events (TEAEs)Time frame: Up to 5 years
  3. Incidence and severity of adverse events of special interest (AESI)Time frame: Up to 5 years
  4. Assessment of the pharmacokinetics (PK) of linvoseltamabTime frame: Up to 5 years
  5. Concentrations of linvoseltamab in serum over timeTime frame: Up to 5 years
  6. Objective response rate (ORR) as determined by an Independent Review Committee (IRC)Time frame: Up to 5 years
  7. Incidence and severity of cytokine release syndrome (CRS) with linvoseltamabTime frame: Up to 5 years
  8. ORR of IV linvoseltamab as assessed by investigatorTime frame: Up to 5 years

Locations

40 sites in 7 countries. Site status is shown where the registry gives one.

  • Sylvester Comprehensive Cancer Center

    Miami, Florida · Active not recruiting

  • Moffitt Cancer Center - McKinley Drive

    Tampa, Florida · Recruiting

  • Emory University Hospital

    Atlanta, Georgia · Recruiting

  • Indiana University_Michigan Street

    Indianapolis, Indiana · Active not recruiting

  • Norton Cancer Institute

    Louisville, Kentucky · Recruiting

  • C. S. Mott_University of Michigan

    Ann Arbor, Michigan · Active not recruiting

  • Barbara Ann Karmanos Cancer Center

    Detroit, Michigan · Active not recruiting

  • Rutgers Cancer Institute of New Jersey

    New Brunswick, New Jersey · Active not recruiting

  • Icahn School of Medicine at Mount Sinai

    New York, New York · Recruiting

  • Columbia University Medical Center

    New York, New York · Active not recruiting

  • Ohio State University James Cancer Hospital

    Columbus, Ohio · Recruiting

  • Oregon Health and Science University (OHSU) Marquam Hill Campus

    Portland, Oregon · Recruiting

  • University of Texas MD Anderson Clinic

    Houston, Texas · Active not recruiting

  • Swedish Cancer Institute

    Seattle, Washington · Recruiting

  • ZNA Psychiatrisch Ziekenhuis Stuivenberg

    Antwerp, Belgium · Recruiting

  • Cliniques Universitaires Saint-Luc

    Brussels, Belgium · Completed

  • Universitatsklinikum Wurzburg

    Würzburg, Germany · Completed

  • Universitatsklinikum Essen

    Essen, North Rhine-Westphalia, Germany · Completed

  • Universitaetsmedizin der Johannes Gutenberg Universitaet Mainz KoeR

    Mainz, Rhineland-Palatinate, Germany · Completed

  • Keio University Hospital

    Tokyo, Japan · Recruiting

  • Japanese Red Cross Aichi Medical Center Nagoya Daini Hospital

    Nagoya, Aichi-ken, Japan · Completed

  • Nagoya City University Hospital

    Nagoya, Aichi-ken, Japan · Recruiting

  • National Cancer Center Hospital East

    Kashiwa-shi, Chiba, Japan · Recruiting

  • Gunma University Hospital

    Maebashi, Gunma, Japan · Recruiting

  • Ibaraki Prefectural Central Hospital

    Kasama-shi, Ibaraki, Japan · Recruiting

  • University Hospital Kyoto Prefectural Univ of Medicine

    Kyoto, Kyoto, Japan · Recruiting

  • Saitama Medical University International Medical Center

    Hidaka, Saitama, Japan · Completed

  • Tokushima Prefectural Central Hospital

    Tokushima, Tokushima, Japan · Recruiting

  • Japanese Red Cross Medical Center

    Shibuya-ku, Tokyo, Japan · Completed

  • National Cancer Center Korea

    Goyang, South Korea · Recruiting

  • Seoul National University Cancer Hospital

    Seoul, South Korea · Recruiting

  • The Catholic University of Korea, Seoul St. Mary's Hospital

    Seoul, South Korea · Recruiting

  • Yonsei University College of Medicine, Severance Hospital

    Seoul, South Korea · Recruiting

  • Hospital Universitario Ramon y Cajal

    Madrid, Spain · Recruiting

  • Hospital Universitario 12 de Octubre

    Madrid, Spain · Recruiting

  • Hospital Clinico Universitario de Salamanca

    Salamanca, Spain · Recruiting

  • Hospital de la Santa Creu i Sant Pau

    Barcelona, Catalonia, Spain · Recruiting

  • Clinica Universidad de Navarra

    Pamplona, Navarre, Spain · Recruiting

  • Universitary Hospital La Princesa

    Madrid, Salamanca, Spain · Recruiting

  • Royal Marsden Hospital

    Sutton, Surrey, United Kingdom · Withdrawn

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.